• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于结构的强效和选择性双溴结构域蛋白 4（BRD4）/丝氨酸苏氨酸激酶 1（PLK1）双重抑制剂的设计与开发。

Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.

机构信息

Department of Chemistry , University of Massachusetts-Boston , Boston , Massachusetts 02125 , United States.

Phase I Clinical Trial Center & Department of Clinical Pharmacology, Xiangya Hospital , Central South University , Changsha , Hunan 410008 , P.R. China.

出版信息

J Med Chem. 2018 Sep 13;61(17):7785-7795. doi: 10.1021/acs.jmedchem.8b00765. Epub 2018 Aug 30.

DOI:10.1021/acs.jmedchem.8b00765
PMID:30125504
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6309379/
Abstract

The simultaneous inhibition of polo-like kinase 1 (PLK1) and BRD4 bromodomain by a single molecule could lead to the development of an effective therapeutic strategy for a variety of diseases in which PLK1 and BRD4 are implicated. Compound 23 has been found to be a potent dual kinase-bromodomain inhibitor (BRD4-BD1 IC = 28 nM, PLK1 IC = 40 nM). Compound 6 was found to be the most selective PLK1 inhibitor over BRD4 in our series (BRD4-BD1 IC = 2579 nM, PLK1 IC = 9.9 nM). Molecular docking studies with 23 and BRD4-BD1/PLK1 as well as with 6 corroborate the biochemical assay results.

摘要

单一分子同时抑制 Polo 样激酶 1（PLK1）和 BRD4 溴结构域，可能为涉及 PLK1 和 BRD4 的多种疾病开发出有效的治疗策略。已发现化合物 23 是一种有效的双重激酶-溴结构域抑制剂（BRD4-BD1 IC = 28 nM，PLK1 IC = 40 nM）。在我们的系列中，化合物 6 被发现是对 BRD4 选择性最高的 PLK1 抑制剂（BRD4-BD1 IC = 2579 nM，PLK1 IC = 9.9 nM）。与 23 和 BRD4-BD1/PLK1 以及与 6 的分子对接研究证实了生化测定结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/6309379/7d22afd4d1a6/nihms-997157-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/6309379/63dbb3f368e4/nihms-997157-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/6309379/927202fd3149/nihms-997157-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/6309379/c8e3b23bb495/nihms-997157-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/6309379/6fb95b980dc4/nihms-997157-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/6309379/4d3cf7d2a60e/nihms-997157-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/6309379/cf4a7edd1950/nihms-997157-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/6309379/b4c1a9ba55ad/nihms-997157-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/6309379/8dcb69de11be/nihms-997157-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/6309379/7d22afd4d1a6/nihms-997157-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/6309379/63dbb3f368e4/nihms-997157-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/6309379/927202fd3149/nihms-997157-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/6309379/c8e3b23bb495/nihms-997157-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/6309379/6fb95b980dc4/nihms-997157-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/6309379/4d3cf7d2a60e/nihms-997157-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/6309379/cf4a7edd1950/nihms-997157-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/6309379/b4c1a9ba55ad/nihms-997157-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/6309379/8dcb69de11be/nihms-997157-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805e/6309379/7d22afd4d1a6/nihms-997157-f0010.jpg

相似文献

1
Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.基于结构的强效和选择性双溴结构域蛋白 4（BRD4）/丝氨酸苏氨酸激酶 1（PLK1）双重抑制剂的设计与开发。
J Med Chem. 2018 Sep 13;61(17):7785-7795. doi: 10.1021/acs.jmedchem.8b00765. Epub 2018 Aug 30.
2
Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.从双重 PLK1-BRD4 抑制剂中发现一系列二氢喹喔啉-2(1H)-酮作为选择性 BET 抑制剂。
Eur J Med Chem. 2017 Sep 8;137:176-195. doi: 10.1016/j.ejmech.2017.05.049. Epub 2017 May 27.
3
Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.设计、合成及生物评价 4,5-二氢-[1,2,4]三唑并[4,3-f]蝶啶衍生物作为新型双 PLK1/BRD4 抑制剂。
Eur J Med Chem. 2020 Apr 1;191:112152. doi: 10.1016/j.ejmech.2020.112152. Epub 2020 Feb 17.
4
Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.靶向急性髓系白血病细胞中双溴结构域蛋白 4（BRD4）和 Polo 样激酶 1（PLK1）的蛋白嵌合体分子。
Biochem Biophys Res Commun. 2020 Jan 22;521(4):833-839. doi: 10.1016/j.bbrc.2019.11.007. Epub 2019 Nov 7.
5
Designed inhibitor for nuclear localization signal of polo-like kinase 1 induces mitotic arrest.针对polo样激酶1核定位信号设计的抑制剂可诱导有丝分裂停滞。
Chem Biol Drug Des. 2017 May;89(5):732-740. doi: 10.1111/cbdd.12896. Epub 2016 Nov 24.
6
Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.非ATP竞争性小分子Polo样激酶1（Plk1）抑制剂的设计、合成与评价
Arch Pharm (Weinheim). 2015 Jan;348(1):2-9. doi: 10.1002/ardp.201400294. Epub 2014 Nov 27.
7
Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.用于调节乳腺癌细胞凋亡和自噬的polo样激酶1/真核生物延伸因子2激酶（PLK1/EEF2K）双重抑制剂的设计、合成及生物学评价
Eur J Med Chem. 2018 Jan 20;144:517-528. doi: 10.1016/j.ejmech.2017.12.046. Epub 2017 Dec 14.
8
Mechanistic Insights into the Selective Dual BET and PLK1 Inhibitory Activity of a Novel Benzamide Compound in Castration-Resistant Prostrate Cancer.新型苯甲酰胺化合物在去势抵抗性前列腺癌中选择性双重 BET 和 PLK1 抑制活性的机制研究。
Chem Biodivers. 2021 Dec;18(12):e2100519. doi: 10.1002/cbdv.202100519. Epub 2021 Nov 16.
9
Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.基于双 BET/PLK1 抑制剂的 AR 阳性前列腺癌中具有强抗增殖作用的选择性 BRD4 PROTAC 的鉴定。
Eur J Med Chem. 2022 Jan 5;227:113922. doi: 10.1016/j.ejmech.2021.113922. Epub 2021 Oct 19.
10
Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1.鉴定靶向 polo 样激酶 1 的 polo 框结构域的新型和选择性非肽抑制剂。
Bioorg Chem. 2018 Dec;81:278-288. doi: 10.1016/j.bioorg.2018.08.030. Epub 2018 Aug 23.

引用本文的文献

1
Thinking Outside the Box: Indirect Myc Modulation in Canine B-Cell Lymphoma.跳出框框思考：犬B细胞淋巴瘤中的间接Myc调节
Animals (Basel). 2024 May 15;14(10):1466. doi: 10.3390/ani14101466.
2
Novel Aminopyrimidine-2,4-diones, 2-Thiopyrimidine-4-ones, and 6-Arylpteridines as Dual-Target Inhibitors of BRD4/PLK1: Design, Synthesis, Cytotoxicity, and Computational Studies.新型氨基嘧啶 -2,4- 二酮、2- 硫代嘧啶 -4- 酮和 6- 芳基蝶啶作为 BRD4/PLK1 的双靶点抑制剂：设计、合成、细胞毒性及计算研究
Pharmaceuticals (Basel). 2023 Sep 15;16(9):1303. doi: 10.3390/ph16091303.
3
Apigenin attenuates depressive-like behavior via modulating monoamine oxidase A enzyme activity in chronically stressed mice.

本文引用的文献

1
Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.PLK1 抑制增强 BET 表观遗传读码器阻断在去势抵抗性前列腺癌中的疗效。
Mol Cancer Ther. 2018 Jul;17(7):1554-1565. doi: 10.1158/1535-7163.MCT-17-0945. Epub 2018 May 1.
2
Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo.BET 抑制剂 BI 894999 与 PLK 抑制剂 volasertib 在 AML 中的体外和体内协同活性。
Cancer Lett. 2018 May 1;421:112-120. doi: 10.1016/j.canlet.2018.02.018. Epub 2018 Feb 14.
3
A chemical probe toolbox for dissecting the cancer epigenome.
芹菜素通过调节慢性应激小鼠体内单胺氧化酶A的酶活性来减轻抑郁样行为。
Curr Res Pharmacol Drug Discov. 2023 Jul 11;5:100161. doi: 10.1016/j.crphar.2023.100161. eCollection 2023.
4
Targeting bromodomain-containing proteins: research advances of drug discovery.靶向含溴结构域蛋白：药物研发的研究进展
Mol Biomed. 2023 May 5;4(1):13. doi: 10.1186/s43556-023-00127-1.
5
Signaling Modulation via Minimal C-Terminal Modifications of Apelin-13.通过对Apelin-13的最小C末端修饰进行信号调节。
ACS Pharmacol Transl Sci. 2023 Jan 26;6(2):290-305. doi: 10.1021/acsptsci.2c00219. eCollection 2023 Feb 10.
6
A Guide to In Silico Drug Design.计算机辅助药物设计指南。
Pharmaceutics. 2022 Dec 23;15(1):49. doi: 10.3390/pharmaceutics15010049.
7
A proteome-wide atlas of drug mechanism of action.药物作用机制的蛋白质组学全景图谱。
Nat Biotechnol. 2023 Jun;41(6):845-857. doi: 10.1038/s41587-022-01539-0. Epub 2023 Jan 2.
8
Molecular Dynamic Simulations of Bromodomain and Extra-Terminal Protein 4 Bonded to Potent Inhibitors.溴结构域和额外末端蛋白 4 与有效抑制剂结合的分子动力学模拟。
Molecules. 2021 Dec 26;27(1):118. doi: 10.3390/molecules27010118.
9
Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma.合成杂环衍生物作为激酶抑制剂，用于神经母细胞瘤的治疗研究。
Molecules. 2021 Nov 23;26(23):7069. doi: 10.3390/molecules26237069.
10
Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors.二氢喋啶酮和嘧啶并哒嗪酮激酶抑制剂对 BET 溴结构域的差异化抑制。
J Med Chem. 2021 Nov 11;64(21):15772-15786. doi: 10.1021/acs.jmedchem.1c01096. Epub 2021 Oct 28.
用于剖析癌症表观基因组的化学探针工具包。
Nat Rev Cancer. 2017 Feb 23;17(3):160-183. doi: 10.1038/nrc.2016.148.
4
Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis.用于对MYC进行正交抑制以阻断肿瘤生长和转移的双活性PI3K-BRD4抑制剂。
Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):E1072-E1080. doi: 10.1073/pnas.1613091114. Epub 2017 Jan 30.
5
Assessment of Bromodomain Target Engagement by a Series of BI2536 Analogues with Miniaturized BET-BRET.采用微型 BET-BRET 评估一系列 BI2536 类似物的溴结构域靶标占有率。
ChemMedChem. 2016 Dec 6;11(23):2575-2581. doi: 10.1002/cmdc.201600502. Epub 2016 Nov 15.
6
Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.“同类首创”双PI3K/BRD4抑制剂SF1126与索拉非尼在肝细胞癌中的单药活性及协同活性
Mol Cancer Ther. 2016 Nov;15(11):2553-2562. doi: 10.1158/1535-7163.MCT-15-0976. Epub 2016 Aug 5.
7
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.Plk1抑制剂在癌症治疗中的应用：从实验室到临床
Mol Cancer Ther. 2016 Jul;15(7):1427-35. doi: 10.1158/1535-7163.MCT-15-0897. Epub 2016 Jun 21.
8
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.三阴性乳腺癌对BET溴结构域抑制剂的反应与耐药性
Nature. 2016 Jan 21;529(7586):413-417. doi: 10.1038/nature16508. Epub 2016 Jan 6.
9
Epigenetics: Place your BETs.表观遗传学：下注你的BET蛋白。 （注：BET可能是一种特定的蛋白或相关分子，具体含义需结合上下文确定，这里只是按字面翻译）
Nat Rev Cancer. 2015 Nov;15(11):638. doi: 10.1038/nrc4035. Epub 2015 Oct 15.
10
BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536.双靶点PLK1激酶/BRD4溴结构域抑制剂BI-2536的BRD4结构-活性关系
ACS Med Chem Lett. 2015 May 18;6(7):764-9. doi: 10.1021/acsmedchemlett.5b00084. eCollection 2015 Jul 9.